Market Research Logo

Tuberculosis - Pipeline Review, H1 2015

Introduction
Tuberculosis Overview
Therapeutics Development
Tuberculosis - Therapeutics under Development by Companies
Tuberculosis - Therapeutics under Investigation by Universities/Institutes
Tuberculosis - Pipeline Products Glance
Tuberculosis - Products under Development by Companies
Tuberculosis - Products under Investigation by Universities/Institutes
Tuberculosis - Companies Involved in Therapeutics Development
Tuberculosis - Therapeutics Assessment
Drug Profiles
Tuberculosis - Recent Pipeline Updates
Tuberculosis - Dormant Projects
Tuberculosis - Discontinued Products
Tuberculosis - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Tuberculosis, H1 2015
Number of Products under Development for Tuberculosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..4)
Tuberculosis - Pipeline by Abera Bioscience AB, H1 2015
Tuberculosis - Pipeline by Achillion Pharmaceuticals, Inc., H1 2015
Tuberculosis - Pipeline by Akthelia pharmaceuticals ehf, H1 2015
Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015
Tuberculosis - Pipeline by Archivel Farma S.L., H1 2015
Tuberculosis - Pipeline by AstraZeneca Plc, H1 2015
Tuberculosis - Pipeline by BioDiem Ltd, H1 2015
Tuberculosis - Pipeline by Biomar Microbial Technologies, H1 2015
Tuberculosis - Pipeline by Bioversys AG, H1 2015
Tuberculosis - Pipeline by Cellceutix Corporation, H1 2015
Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015
Tuberculosis - Pipeline by CureVac GmbH, H1 2015
Tuberculosis - Pipeline by Dafra Pharma International Ltd., H1 2015
Tuberculosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Tuberculosis - Pipeline by Eisai Co., Ltd., H1 2015
Tuberculosis - Pipeline by Eli Lilly and Company, H1 2015
Tuberculosis - Pipeline by Ensoltek Co., Ltd., H1 2015
Tuberculosis - Pipeline by EpiVax, Inc., H1 2015
Tuberculosis - Pipeline by FIT Biotech Oy, H1 2015
Tuberculosis - Pipeline by GangaGen Inc., H1 2015
Tuberculosis - Pipeline by GlaxoSmithKline Plc, H1 2015
Tuberculosis - Pipeline by Globeimmune, Inc., H1 2015
Tuberculosis - Pipeline by Imaxio SA, H1 2015
Tuberculosis - Pipeline by Immunitor, Inc., H1 2015
Tuberculosis - Pipeline by ImmunoBiology Limited, H1 2015
Tuberculosis - Pipeline by Immunovaccine, Inc., H1 2015
Tuberculosis - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015
Tuberculosis - Pipeline by iThemba Pharmaceuticals (Pty) Ltd., H1 2015
Tuberculosis - Pipeline by Johnson & Johnson, H1 2015
Tuberculosis - Pipeline by Lipotek Pty Ltd., H1 2015
Tuberculosis - Pipeline by Microbion Corporation, H1 2015
Tuberculosis - Pipeline by Microbiotix, Inc., H1 2015
Tuberculosis - Pipeline by NEARMEDIC PLUS, Ltd, H1 2015
Tuberculosis - Pipeline by Novartis AG, H1 2015
Tuberculosis - Pipeline by Okklo Life Sciences BV, H1 2015
Tuberculosis - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2015
Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Tuberculosis - Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H1 2015
Tuberculosis - Pipeline by Prokarium Limited, H1 2015
Tuberculosis - Pipeline by Sanofi, H1 2015
Tuberculosis - Pipeline by Sanofi Pasteur SA, H1 2015
Tuberculosis - Pipeline by Sarepta Therapeutics, Inc., H1 2015
Tuberculosis - Pipeline by SEEK Group, H1 2015
Tuberculosis - Pipeline by Sequella, Inc., H1 2015
Tuberculosis - Pipeline by Snowdon Inc., H1 2015
Tuberculosis - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2015
Tuberculosis - Pipeline by Syntrix Biosystems, Inc., H1 2015
Tuberculosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Tuberculosis - Pipeline by TetraLogic Pharmaceuticals, H1 2015
Tuberculosis - Pipeline by Theravectys S.A., H1 2015
Tuberculosis - Pipeline by Transgene SA, H1 2015
Tuberculosis - Pipeline by TVAX Biomedical, Inc., H1 2015
Tuberculosis - Pipeline by Vaccibody AS, H1 2015
Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H1 2015
Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2015
Tuberculosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015
Tuberculosis - Pipeline by Vichem Chemie Research Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Tuberculosis Therapeutics - Recent Pipeline Updates, H1 2015
Tuberculosis - Dormant Projects, H1 2015
Tuberculosis - Dormant Projects (Contd..1), H1 2015
Tuberculosis - Dormant Projects (Contd..2), H1 2015
Tuberculosis - Dormant Projects (Contd..3), H1 2015
Tuberculosis - Dormant Projects (Contd..4), H1 2015
Tuberculosis - Dormant Projects (Contd..5), H1 2015
Tuberculosis - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Tuberculosis, H1 2015
Number of Products under Development for Tuberculosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Tuberculosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Tuberculosis - Pipeline Review, H1 2015’, provides an overview of the Tuberculosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tuberculosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Tuberculosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Tuberculosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;